Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Pivotal Trials in the Realm of Ovarian Cancer
TESARO Pioneers Summit - ppt download
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial - Mirza - 2023 - Cancer - Wiley Online Library
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Niraparib in Patients With Newly Diagnosed Advanced Ovarian BRCAm Cancer: A Post Hoc Analysis of the PRIMA/ENGOT-OV26/GOG-3012 T
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
Treatment Considerations With Niraparib
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
PARP Inhibitors. - ppt download
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Treatment and Maintenance Therapy in Advanced Ovarian Cancer | VuMedi
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer | PPT
